Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TScan Therapeutics ( (TCRX)) has shared ...

TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers. The company had ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from TScan ...

WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell ...

(MENAFN- GlobeNewsWire - Nasdaq) Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, ...

TScan Therapeutics, Inc. (NASDAQ:TCRX) shares are trading higher in the premarket session on Thursday. The firm announced a significant financing deal, entering into a securities purchase agreement ...

Jason A. Amello, TScan's CFO, highlighted the impact of the investment on the company's financial runway, stating that the additional $30 million in gross proceeds is expected to extend TScan's ...

WALTHAM, MA - TScan Therapeutics, Inc. (NASDAQ:TCRX), a biotechnology firm specializing in biological products, has entered into a significant lease expansion to support its operations. The company ...

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...